Levosimendan Administration and Outcome in Cardiac Surgery
Completed
- Conditions
- Treatment of Left Heart Insufficiency in an Operative Setting of Cardiac Surgery
- Interventions
- Registration Number
- NCT02275013
- Lead Sponsor
- Charite University, Berlin, Germany
- Brief Summary
To assess the effects on outcome of levosimendan with respect to timing of its administration on the postoperative course of high-risk cardiac surgery patients in a retrospective observational study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 159
Inclusion Criteria
- patients undergoing cardiac surgery between 2006 and 2013
- levosimendan administration within 24 hours of postoperative ICU admission
Read More
Exclusion Criteria
- patients younger than 18
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Early Levosimendan Levosimendan administration within first hour of post-operative ICU admission Late Levosimendan Levosimendan administration within 24 hours of post-operative ICU admission but after first hour
- Primary Outcome Measures
Name Time Method In-hospital mortality until discharge, an average of 3 weeks length of stay 1 year follow-up mortality 1 year after surgery
- Secondary Outcome Measures
Name Time Method Duration of mechanical ventilation until discharge, an average of 3 weeks length of stay Incidence of renal dysfunction until discharge, an average of 3 weeks length of stay Incidence of renal replacement therapy until discharge, an average of 3 weeks length of stay
Trial Locations
- Locations (1)
Charité University Medicine
🇩🇪Berlin, Germany